004720 — PharmGen Science Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapContrarian

Annual income statement for PharmGen Science, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	95,138	96,614	109,866	150,931	166,779
Cost of Revenue
Gross Profit	50,400	53,599	60,803	81,302	97,869
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	93,301	94,996	116,138	144,570	158,617
Operating Profit	1,837	1,618	-6,272	6,361	8,162
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	404	11,209	41,949	89,960	7,991
Provision for Income Taxes
Net Income After Taxes	236	9,124	32,414	70,058	5,726
Minority Interest
Net Income Before Extraordinary Items
Net Income	302	9,222	32,466	70,060	5,727
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	302	9,364	32,466	70,060	6,369
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-11.3	501	1,797	3,285	338
Dividends per Share